Compare Stocks: LLY, DXCM, GRMN, and AAPL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPL Apple	$339.60 +0.2%	$320.67	$243.42 ▼ $345.34	$4.96T	1.08	49.71 million shs	28.09 million shs
DXCM DexCom	$89.47 +0.3%	$84.36	$54.11 ▼ $92.59	$33.76B	1.42	5.14 million shs	4.53 million shs
GRMN Garmin	$284.64 +1.5%	$280.47	$186.67 ▼ $314.28	$54.89B	0.85	907,207 shs	908,513 shs
LLY Eli Lilly and Company	$1,171.48 +0.6%	$1,176.50	$712.05 ▼ $1,292.65	$1.10T	0.5	3.02 million shs	1.76 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPL Apple	+0.85%	+1.77%	+9.58%	+14.92%	+38.08%
DXCM DexCom	-0.20%	+5.30%	-3.43%	+29.34%	+32.20%
GRMN Garmin	+2.24%	-0.24%	-5.00%	+18.38%	+19.15%
LLY Eli Lilly and Company	+1.13%	+2.34%	-7.29%	+4.98%	+54.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPL Apple	$339.60 +0.2%	$320.67	$243.42 ▼ $345.34	$4.96T	1.08	49.71 million shs	28.09 million shs
DXCM DexCom	$89.47 +0.3%	$84.36	$54.11 ▼ $92.59	$33.76B	1.42	5.14 million shs	4.53 million shs
GRMN Garmin	$284.64 +1.5%	$280.47	$186.67 ▼ $314.28	$54.89B	0.85	907,207 shs	908,513 shs
LLY Eli Lilly and Company	$1,171.48 +0.6%	$1,176.50	$712.05 ▼ $1,292.65	$1.10T	0.5	3.02 million shs	1.76 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPL Apple	+0.85%	+1.77%	+9.58%	+14.92%	+38.08%
DXCM DexCom	-0.20%	+5.30%	-3.43%	+29.34%	+32.20%
GRMN Garmin	+2.24%	-0.24%	-5.00%	+18.38%	+19.15%
LLY Eli Lilly and Company	+1.13%	+2.34%	-7.29%	+4.98%	+54.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPL Apple	2.62	Moderate Buy	$340.14	-0.30% Downside
DXCM DexCom	2.92	Moderate Buy	$89.08	-0.89% Downside
GRMN Garmin	2.75	Moderate Buy	$310.17	9.82% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,305.25	11.49% Upside

Current Analyst Ratings Breakdown

Latest LLY, DXCM, GRMN, and AAPL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	LLY Eli Lilly and Company	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$1,250.00
9/18/2026	AAPL Apple	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
9/18/2026	DXCM DexCom	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$93.00 ➝ $102.00
9/18/2026	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,273.00 ➝ $1,284.00
9/18/2026	AAPL Apple	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Outperform	$365.00 ➝ $380.00
9/18/2026	AAPL Apple	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$380.00
9/18/2026	DXCM DexCom	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
9/17/2026	AAPL Apple	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	AAPL Apple	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$370.00
9/15/2026	LLY Eli Lilly and Company	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Hold ➝ Buy	$1,400.00
9/15/2026	LLY Eli Lilly and Company	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$1,400.00

(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPL Apple	$416.16B	11.96	$8.50 per share	40.15	$4.99 per share	68.37
DXCM DexCom	$4.66B	7.28	$2.79 per share	32.27	$7.04 per share	12.77
GRMN Garmin	$7.25B	7.52	$9.89 per share	28.55	$46.65 per share	6.05
LLY Eli Lilly and Company	$79.67B	13.83	$25.53 per share	45.86	$28.07 per share	41.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPL Apple	$112.01B	$8.72	39.14	35.80	2.92	27.62%	135.46%	34.11%	10/29/2026 (Estimated)
DXCM DexCom	$836.30M	$2.53	35.53	29.18	1.50	20.12%	35.94%	14.75%	10/29/2026 (Estimated)
GRMN Garmin	$1.66B	$9.70	29.13	26.39	3.06	24.47%	20.95%	17.06%	11/4/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	39.28	25.36	1.42	33.53%	97.83%	23.23%	10/29/2026 (Estimated)

Latest LLY, DXCM, GRMN, and AAPL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
7/30/2026	Q3 2026	AAPL Apple	$1.89	$2.02	+$0.13	$2.02	$109.04 billion	$109.42 billion
7/30/2026	Q2 2026	DXCM DexCom	$0.6110	$0.70	+$0.0890	$0.64	$1.29 billion	$1.31 billion
7/30/2026	Q2 2026	GRMN Garmin	$2.30	$2.81	+$0.51	$2.80	$1.93 billion	$2.02 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPL Apple	$1.08	0.32%	+4.98%	12.39%	14 Years
DXCM DexCom	N/A	N/A	N/A	N/A	N/A
GRMN Garmin	$4.20	1.49%	+7.53%	43.30%	8 Years
LLY Eli Lilly and Company	$6.92	0.59%	+15.18%	23.22%	11 Years

Latest LLY, DXCM, GRMN, and AAPL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
7/30/2026	AAPL Apple	quarterly	$0.27	0.35%	8/10/2026	8/10/2026	8/13/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPL Apple	0.66	1.00	0.93
DXCM DexCom	0.47	1.73	1.43
GRMN Garmin	N/A	3.03	2.08
LLY Eli Lilly and Company	1.41	1.35	1.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPL Apple	67.73%
DXCM DexCom	97.75%
GRMN Garmin	81.60%
LLY Eli Lilly and Company	82.53%

Insider Ownership

Company	Insider Ownership
AAPL Apple	0.06%
DXCM DexCom	0.28%
GRMN Garmin	14.80%
LLY Eli Lilly and Company	0.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPL Apple	166,000	14.59 billion	14.59 billion	Optionable
DXCM DexCom	11,000	377.36 million	376.30 million	Optionable
GRMN Garmin	23,000	192.85 million	164.31 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable

LLY, DXCM, GRMN, and AAPL Headlines

Recent News About These Companies

Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

...

1 hour ago | marketbeat.com

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

2 hours ago | benzinga.com

Viking Soars Alone as Obesity Complex Shrugs at Strong GLP-1 Results

2 hours ago | 247wallst.com

State Street Corp Increases Position in Eli Lilly and Company $LLY

3 hours ago | marketbeat.com

Andra AP fonden Lowers Holdings in Eli Lilly and Company $LLY

3 hours ago | marketbeat.com

Eli Lilly Breaks Ground On $6.5 Bln Houston Manufacturing Facility

3 hours ago | rttnews.com

Eli Lilly Breaks Ground on $6.5B GLP-1 Manufacturing Facility in Northeast Houston

3 hours ago | rebusinessonline.comR

Lilly presents early data supporting GLP-1/GIP candidate’s potential in depression, alcohol use disorder

3 hours ago | biospace.comB

Eli Lilly CEO Delivers Urgent Message on the Company's Next Big Weight-Loss Pill

3 hours ago | finance.yahoo.com

Eli Lilly Breaks Ground on $6.5B Generation Park Facility

3 hours ago | credaily.comC

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth?

3 hours ago | fool.com

Eli Lilly Completes Key Phase 1 Study of Remternetug in China: What Investors Should Watch Next

3 hours ago | tipranks.com

Eli Lilly’s New Obesity Candidate LY4329090: Early Trial Update and Investor Watchpoints

3 hours ago | tipranks.com

Novo's CagriSema Outshines Zepbound in Key Phase III Weight-Loss Study

4 hours ago | zacks.com

This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month

4 hours ago | marketwatch.com

His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000

September 22 at 10:10 AM | 247wallst.com

His Bet On Home Depot Made Ken Langone A Billionaire. Now He Sees Eli Lilly Stock Hitting $2,000

September 22 at 10:09 AM | 247wallst.com

Viking Therapeutics Stock Surges 36%. It Could Challenge Lilly and Novo's Obesity Empire.

September 22 at 8:22 AM | barrons.com

Eli Lilly CEO Says Foundayo Wins One-Third of New Oral GLP-1 Patients as Company Captures 70% of New Seniors: 'Growing Week on Week'

September 22 at 8:11 AM | benzinga.com

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.

September 22 at 8:00 AM | finance.yahoo.com

Eli Lilly’s Tough Month: One of The Biggest Global Banks Says 37% Gains Begin Soon

September 22 at 7:51 AM | 247wallst.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LLY, DXCM, GRMN, and AAPL Company Descriptions

Apple NASDAQ:AAPL

$339.60 +0.62 (+0.18%)

Closing price 03:59 PM Eastern

Extended Trading

$339.91 +0.32 (+0.09%)

As of 04:11 PM Eastern

Apple Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide. The company offers iPhone, a line of smartphones; Mac, a line of personal computers; iPad, a line of multi-purpose tablets; and wearables, home, and accessories comprising AirPods, Apple TV, Apple Watch, Beats products, and HomePod. It also provides AppleCare support and cloud services; and operates various platforms, including the App Store that allow customers to discover and download applications and digital content, such as books, music, video, games, and podcasts. In addition, the company offers various services, such as Apple Arcade, a game subscription service; Apple Fitness+, a personalized fitness service; Apple Music, which offers users a curated listening experience with on-demand radio stations; Apple News+, a subscription news and magazine service; Apple TV+, which offers exclusive original content; Apple Card, a co-branded credit card; and Apple Pay, a cashless payment service, as well as licenses its intellectual property. The company serves consumers, and small and mid-sized businesses; and the education, enterprise, and government markets. It distributes third-party applications for its products through the App Store. The company also sells its products through its retail and online stores, and direct sales force; and third-party cellular network carriers, wholesalers, retailers, and resellers. Apple Inc. was founded in 1976 and is headquartered in Cupertino, California.

DexCom NASDAQ:DXCM

$89.47 +0.30 (+0.34%)

Closing price 03:59 PM Eastern

Extended Trading

$89.49 +0.02 (+0.02%)

As of 04:10 PM Eastern

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Garmin NYSE:GRMN

$284.64 +4.33 (+1.55%)

Closing price 03:59 PM Eastern

Extended Trading

$283.90 -0.74 (-0.26%)

As of 04:10 PM Eastern

Garmin Ltd. designs, develops, manufactures, markets, and distributes a range of wireless devices worldwide. Its Fitness segment offers running and multi-sport watches; cycling products; smartwatch devices; scales and monitors; and fitness accessories. This segment also provides Garmin Connect and Garmin Connect Mobile, which are web and mobile platforms where users can track and analyze their fitness, activities and workouts, and wellness data; and Connect IQ, an application development platform. The company's Outdoor segment offers adventure watches, outdoor handhelds and satellite communicators, golf devices, consumer automotive devices, and dog devices, as well as InReach and Gramin response communication device. Its Aviation segment designs, manufactures, and markets various aircraft avionics solutions, including integrated flight decks, electronic flight displays and instrumentation, navigation and communication products, automatic flight control systems and safety-enhancing technologies, audio control systems, engine indication systems, traffic awareness and avoidance solutions, ADS-B and transponders, weather information and avoidance solutions, datalink and connectivity solutions, and various services. The company's Marine segment provides chartplotters and multi-function displays, cartography products, fishfinders, sonar products, autopilot systems, radars, compliant instrument displays and sensors, VHF communication radios, handhelds and wearable devices, sailing products, audio products and accessories, digital switching products, and trolling motors. Its Auto segment offers embedded domain controllers and infotainment units; and software, map database, cameras, wearables, and automotive solutions. The company sells its products through independent retailers, dealers, distributors, installation and repair shops, and original equipment manufacturers, as well as online webshop. Garmin Ltd. was founded in 1989 and is based in Schaffhausen, Switzerland.

Eli Lilly and Company NYSE:LLY

$1,171.48 +6.59 (+0.57%)

Closing price 03:59 PM Eastern

Extended Trading

$1,171.18 -0.30 (-0.03%)

As of 04:11 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LLY, DXCM, GRMN, and AAPL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LLY, DXCM, GRMN, and AAPL Earnings

Compare Dividends

Latest LLY, DXCM, GRMN, and AAPL Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LLY, DXCM, GRMN, and AAPL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LLY, DXCM, GRMN, and AAPL Company Descriptions

Apple NASDAQ:AAPL

DexCom NASDAQ:DXCM

Garmin NYSE:GRMN

Eli Lilly and Company NYSE:LLY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools